Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK2 V617F |
| Therapy | Imatinib |
| Indication/Tumor Type | myeloid leukemia |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK2 V617F | myeloid leukemia | resistant | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, mouse myeloid cells expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473). | 21224473 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21224473) | Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. | Full reference... |